Adrenoleukodystrophy Market
As per DelveInsight’s epidemiological analysis, Adrenoleukodystrophy prevalence in the 7MM (the US, EU5 (the UK, Germany, France, Italy and Spain) and Japan) was estimated to be 55,242 in 2017.
DelveInsight reckons an increase in the global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 million in the 7MM in 2017.
Some of the Key pharma players involved in the development of therapies to address the unmet needs prevailing in the Adrenoleukodystrophy market include Bluebird Bio, Minoryx Therapeutics, Medday Pharmaceuticals, Magenta Therapeutics, and others.
For more details visit: https://www.delveinsight.com/blog/adrenoleukodystrophy-market-size/
Essential Thrombocythemia Market
The total prevalent population of Essential Thrombocythemia (ET) in 2017 was 232,688 in the seven major markets.
With 142,635 cases in 2017, the United States registered the highest prevalent population of Essential Thrombocythemia among the 7MM. Out of all the cases in the United States (in 2017), it is being observed that the age-group of 60-80 years accounted for the highest cases of Essential Thrombocythemia.
The market size of Essential Thrombocythemia (ET) was found to be USD 616.05 Million in 2017, which is expected to increase during the forecast period 2017-2030.
The key players in the Essential Thrombocythemia Market includes PharmaEssentia, Eli Lilly and Company, Novartis, Geron Corporation, Italfarmaco, Imago BioSciences, Galena Pharma, and many others.
For more details visit: https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights
Covid-19 Vaccine Candidate In India
India registered its first COVID19 case on 30-January-2020, since then the cases are on continuous rise. On 29-July-2020 the tally of total cases has crossed the figure of 1.50 Million with more than 30 thousand casualties.
Several pharma and biotech companies are developing and manufacturing safe and effective vaccines to fight coronavirus. In The Global race for the COVID-19 (CoronaVirus) vaccine, India Stands as a strong player.
Currently, India has more than 25 companies invested in the COVID 19 (Novel Coronavirus 19 ) vaccine development.
Some of the Indian companies with their vaccine in the different testing and clinical phases includes Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Zydus Group, Mynvax Private Limited, Biological E. Limited, Indian Immunologicals Limited, Panacea Biotec and others.
For more details on Covid-19 vaccine candidate in india, visit: https://www.delveinsight.com/blog/covid-19-vaccine-in-india/
Chronic Kidney Disease Market
In 2017, the total prevalent population of Chronic Kidney Disease (CKD) was found to be 122,704,658 in the seven major markets. The prevalent population of Chronic Kidney Disease in the United States was 35,288,932 while Japan had 21,183,442 prevalent cases of CKD in 2017.
The market size of Chronic Kidney Disease (CKD) in the 7MM is estimated to be USD 16,897.5 Million by 2030.
Some of the key players in the Chronic Kidney Disease (CKD) market includes GlaxoSmithKline, Akebia Therapeutics, Tricida Pharma, AstraZeneca, FibroGen, Astellas Pharma, Corvidia Therapeutics, Boehringer Ingelheim, Reata Pharmaceuticals and many others.
For more details on Chronic Kidney Disease Market, visit: https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market
Frontotemporal Dementia Market
As per the NORD, Frontotemporal degeneration affects around 50,000-60,000 people in the United States. As per the DelveInsight, the total number of Frontotemporal prevalent cases in the seven major markets was found to be 76,499 in the year 2017.
The Frontotemporal Dementia market is expected to increase with a CAGR of 21.41% for the seven major markets [i.e. the USA, EU5 ( the UK, Germany, France, Italy, and Spain)] during the study period.
Some of the key pharma companies such as TauRx Therapeutics, Axon Neuroscience SE, Prevail Therapeutics, Avid Radiopharmaceuticals, and Alector are actively working to build up the Frontotemporal dementia pipeline.
For more detailed information on Frontotemporal dementia market, visit:
https://www.delveinsight.com/blog/frontotemporal-dementia-market/
Complement 3 Glomerulopathy (C3G) Market
The total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in 2017 was 8,175 in the seven major markets. In 2017, the United States accounted for the highest diagnosed prevalent cases of C3G with 3,967 cases.
The market size of Complement 3 Glomerulopathy (C3G) in 7MM was USD 40.6 Million in 2017, which is expected to increase during the study period 2017-2030.
The key players in the Complement 3 Glomerulopathy (C3G) Market include Alexion Pharmaceuticals, Omeros, Apellis Pharma, Novartis and many others.
For more details visit: https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
Acromegaly Market
The total prevalent cases of Acromegaly in 2017 was 64,508 in seven major markets. In 2017, the prevalent population of Acromegaly in the United States was found to be 28,671 cases while Japan has around 10,690 prevalent cases. The EU5 countries (i.e. the UK, Spain, Germany, France, and Italy) occupied nearly 38.98% of the patient pool amongst 7MM in 2017.
The market size of Acromegaly was estimated to be USD 956.96 Million in 2017 in the 7MM, which is expected to increase during the study period 2017-2030.
The key players in the Acromegaly market includes Ionis Pharmaceuticals, Chiasma Pharma, Strongbridge Biopharma, Antisense Therapeutics, Crinetics Pharmaceuticals, Midatech Pharma, Camurus, Ipsen, GlyTech, Inc. and many others.
For more detailed information on Acromegaly Market, visit: https://www.delveinsight.com/report-store/acromegaly-market
Familial Chylomicronemia Syndrome Market Analysis
The total Familial chylomicronemia syndrome prevalent population in the 7MM (the US, EU5 (the UK, Germany, France, Spain, and Italy) and Japan) was assessed to be 5,801 in 2017.
The current Familial Chylomicronemia Syndrome market is mainly dominated by traditional TG-lowering agents, and as per DelveInsight analysis, the market worth was estimated to be USD 1.0 million in 2017.
Some of the leading pharma players working towards the development of better treatment approaches for FCS patients include Akcea Therapeutics, Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Amryt Pharma plc and others.
For more details visit: https://www.delveinsight.com/blog/familial-chylomicronemia-syndrome-market/
Non-Muscle Invasive Bladder Cancer (NMIBC) Market
The total diagnosed prevalent population of Non-Muscle Invasive Bladder Cancer (NMIBC) in 7MM was 533,263 in 2017. The diagnosed prevalent population of NMIBC in Japan in 2017 was 74,691.
The EU5 countries ( i.e the Uk, Spain, France, Germany, Italy) occupied approximately 45.90% of the patient pool amongst seven major markets.
The market size of Non-Muscle Invasive Bladder Cancer (NMIBC) in 7MM was found to be USD 1,454 Million in 2017, which is expected to increase during the study period 2017-2030.
The key pharma players in the Non-Muscle Invasive Bladder Cancer (NMIBC) Market includes Sesen Bio, Bristol-Myers Squibb,Janssen Pharmaceutical, Ferring Pharmaceuticals, FKD Therapies, AstraZeneca, Celgene,Hamlet Pharma, Roche, UroGen Pharma, ImmunityBio, Altor BioScience, TesoRx Pharma, Pfizer, Incyte Corporation, Theralase,Spectrum Pharmaceuticals, CG Oncology, EMD Serono and many others.
For more details visit: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
Internet Of Things in healthcare
Internet Of Things is the next big entity in the healthcare system, set to completely revolutionize the healthcare delivery and design system in the coming future years. The main focus of IoT is to prevent disease rather than curing it.
IoT has a promising future, since the technology is in the initial phase right now, many big players whether investors or manufacturers to fulfill the user’s and organisation needs are working in the development of IoT based healthcare services.
Some of the key players in the IoT (healthcare field) include STANLEY Healthcare, GE Healthcare, Resideo, Cisco, Medtronic, Philips and many others.
For more details visit: https://www.delveinsight.com/blog/iot-in-healthcare/
Exocrine Pancreatic Insufficiency Market
The prevalence of causative Indications of Exocrine Pancreatic Insufficiency observed in Type II Diabetes Mellitus in 2017 was 67,892,836 in the seven major markets.
The market size of Exocrine Pancreatic Insufficiency in the 7MM was found to be USD 1,695.26 Million in 2107, which is expected to increase during the forecast period 2017-2030.
The key players in the Exocrine Pancreatic Insufficiency market include Digestive CARE®, AbbVie, Alcresta Therapeutics, Nestlé, Aptalis Pharmaceutical, Janssen Pharmaceutica and many others.
For more detailed information on Exocrine Pancreatic Insufficiency Market, visit:
https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-market
C-Met mutated NSCLC Market
The total incident cases of C-Met mutated NSCLC in the 7MM was 16,658 in 2017. The C-Met accounted for approximately 4% of the total cases of NSCLC. In 2017, with 7,202 cases the United States had the highest number of C-Met mutated NSCLC cases among the 7MM, while Spain with 869 cases had the lowest registered cases.
The market size of C-Met mutated NSCLC in the 7MM was found to be USD 186 Million in 2017, which is expected to increase during the forecast period 2017-2030.
The key companies in the C-Met mutated NSCLC market includes Novartis, Merck, Janssen Pharmaceutical, Eli Lilly and Company, AbbVie, Symphogen, Takeda, Exelixis, Ipsen and others.
For more detailed information, visit: https://www.delveinsight.com/report-store/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market
Acute Renal Failure Pipeline Analysis
The significant unmet need that encompasses Acute Kidney Injury is that currently, neither there are any proven therapeutic strategies to reduce Acute Kidney Injury sequelae, nor affirmed robust evidence till date to inform strategy for the provision of healthcare.
The key players involved in developing promising therapeutic interventions to treat the Acute Kidney Injury includes: Alloksys Life Sciences BV, Angion, Quark Pharmaceuticals, AM-Pharma, Atox Bio, Exponential Biotherapies, Inc., MediBeacon Inc., Astellas Pharma US, and Pharming Technologies B.V.
The key emerging therapies in the Acute Kidney Injury pipeline will substantially provide a better outlook for the AKI treatment market to prosper and ultimately focus on addressing all the unmet needs surrounding the condition.
For more detailed information visit:
https://www.delveinsight.com/blog/acute-kidney-injury-pipeline/
BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market
The total incident cases of BRAF Mutated Non-small Cell Lung Cancer (NSCLC) in the 7MM was 19,275 in 2017. BRAF Mutated NSCLC accounted for around 5% of the total cases of NSCLC. In 2017 with 8,979 cases the United states accounted for the highest number of cases of BRAF Mutated NSCLC while Japan with around 1,000 cases had the lowest number of cases among seven major markets.
The market size of BRAF Mutated Non-small Cell Lung Cancer in 7MM was found to be USD 273 Million in 2017, which is expected to increase during the forecast period 2017-2030.
Some of the key players in the BRAF Mutated NSCLC market include Roche, Pfizer, Novartis and many others.
For more details visit: https://www.delveinsight.com/report-store/braf-mutated-non-small-cell-lung-cancer-market
Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market
The total incident population of Non-Small Cell Lung Cancer (NSCLC) in the seven major markets was 484,726 in 2017. The incident cases of ALK- positive mutation in the United states in 2017 was found to be 8,449.The United States accounts for around 38% of the total patient population of ALK-positive NSCLC among the 7MM.
The total market size of Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) in the 7MM was USD 841 Million in 2017, which is expected to increase during the study period 2017-2030.
Some of the key companies in the ALK-NSCLC market include Pfizer, Takeda, Roche, Xcovery and many others.
For more detailed information visit: https://www.delveinsight.com/report-store/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market
Vernal keratoconjunctivitis Market Outlook
The Vernal keratoconjunctivitis prevalence in the 7 Major Markets (the United States, EU5 (the United Kingdom, Spain, Germany, Italy, France) and Japan), China, Egypt, Saudi Arabia, and Russia was estimated to be 4,752,356 in 2017.
Among all the geographies, China accounted for the maximum Vernal keratoconjunctivitis prevalence with 2,248,706 cases. In 2017, in the US the Vernal keratoconjunctivitis prevalence was estimated to be 65,309.
The present Vernal keratoconjunctivitis market size in all the markets (the US, EU-5 (Germany, France, Italy, Spain, United Kingdom), Japan, China, MEA (Saudi Arabia, Egypt), and Russia) was estimated to be USD 307.89 million in 2017 and is anticipated to increase during the forecast period 2017-2030.
Some of the key pharma companies such as Allakos, iCo Therapeutics, Akari Therapeutics, and Santen, are proactively working to advance the Vernal keratoconjunctivitis market forward.
For more information on Vernal keratoconjunctivitis market, visit:
https://www.delveinsight.com/blog/vernal-keratoconjunctivitis-vkc-market/
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market
The total incident population of Non Small Cell Lung Cancer in the seven major markets was 484,726 in 2017. The incident cases of EGFR mutation in the United States in 2017 was 37,370.
In 2017, it was observed that the incident population of EGFR-NSCLC in the United States contributed around 34% of the total population of EGFR mutated NSCLC in the 7MM.
The total market size of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market in the 7MM was found to be USD 1,893 Million in 2017, which is expected to increase during the forecast period 2017-2030.
The key companies in the EGFR-NSCLC market include Novartis, Yuhan Pharmaceutical, Janssen Pharmaceutica, Takeda, Pfizer, AstraZeneca and many others.
For more detailed information on EGFR-NSCLC market visit: https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market
Peripheral T-Cell Lymphoma (PTCL) Market
In 2017, the total incident population of Peripheral T-Cell Lymphoma (PTCL) in 7MM was 16,298.
The market size of Peripheral T-Cell Lymphoma (PTCL) in 7MM was found to be USD 815.38 Million in 2017, which is expected to increase during the forecast period 2017-2030.
The key players in the Peripheral T-Cell Lymphoma (PTCL) market includes Eisai, Verastem Oncology, Affimed, Aileron Therapeutics, Solasia Pharma, Genor Biopharma, Bristol-Myers Squibb, AB Science, CerRx Inc., Celgene, Pfizer, Novartis/Incyte, Kura Oncology, BeiGene, Merck, PharmaMar, HUYA Bioscience International, Innate Pharma, Sorrento Therapeutics, Astex Pharmaceuticals, Otsuka Pharmaceutical and others.
For more detailed information on Peripheral T-Cell Lymphoma (PTCL) Market, visit:
https://www.delveinsight.com/report-store/peripheral-t-cell-lymphoma-ptcl-market
Dravet Syndrome Market
The total incident population of Dravet Syndrome in the seven major markets was 30,820 in 2017.
Similarly, of all the Dravet Syndrome patients in the 7MM, the United States registered around 20,912 patients while Japan had nearly 2,766 patients during the year 2017.
The market size of Dravet Syndrome in 7MM in 2017 was found to be USD 79.1 Million, which is expected to grow during the forecast period 2017-2030.
The key players in the Dravet Syndrome market include Zogenix, Ovid Therapeutics, PTC Therapeutics, Biocodex, GW Pharmaceuticals and others.
For more detailed information on Dravet Syndrome Market, visit: https://www.delveinsight.com/report-store/dravet-syndrome-market
Leading Causes Of Deaths In The World
In 2016, nearly 56.9 million deaths occurred due to the top 10 diseases in the world. The majority of these deaths (nearly two-third) are related to chronic disease such Ischemic heart disease/coronary artery disease (stroke), chronic obstructive pulmonary disease, and diabetes etc.
Some of the most deadliest diseases in the world which took highest number of lives in 2016 includes Ischemic Heart Disease, strokes, Chronic Obstructive Pulmonary Disease, Lower Respiratory Infections, Diabetes, Diarrheal Diseases, Tuberculosis, Trachea, Bronchus and Lung cancers,
For some disease like HIV/AIDS, diarrheal diseases, tuberculosis the number of crude death rate has reduced significantly while for some disease like Diabetes it has increased, which a major cause of concern as diabetes give rise to many other diseases such as blindness, kidney failure, heart attacks, stroke and many other conditions.
For more detailed information on Leading Causes of Deaths in the World, visit:
https://www.delveinsight.com/blog/leading-causes-of-deaths-in-the-world/
Joined Feb 2020
